News
Public · Published
Contineum Therapeutics, Inc. Stock 12‑Month Price Target Cut to $21.43, Implies 121% Upside
Analysts lowered Contineum Therapeutics' average 12-month stock price target from $22.14 to $21.43, with estimates ranging from $14 to $30 per share. Based on the November 3 closing price, the new average target implies about 121% potential upside. The consensus rating remained Buy.
Published:
Updated:
What happened
Analysts lowered Contineum Therapeutics’ average 12-month stock price target from $22.14 to $21.43, with estimates ranging from $14 to $30 per share. Based on the November 3 closing price, the new average target implies about 121% potential upside. The consensus rating remained Buy.
Confirmed
Global impact / market context
The lower target signals that analysts’ average valuation has weakened, even though it still sits far above the reference closing price. If investors act on that gap, their buying or selling could affect the stock, while the forecasts themselves do not guarantee future returns.
Analyst inference
The report cites seven analysts for the average target and eight for the consensus rating, so the figures reflect differing analyst groups. Six analysts rated the stock Buy and two Hold, with none rating it Sell; the article gives no company operating or financial results.
Confirmed
What to watch
- Check whether later analyst updates move the average target or change the $14-to-$30 forecast range; shifts could show whether views are converging or diverging. Analyst inference
- Watch for changes in the consensus rating and the balance of Buy, Hold, and Sell recommendations among the analysts covering the stock. Analyst inference
- Compare future analyst targets with the stock’s then-current price and company disclosures; the reported 121% upside is tied specifically to the November 3 closing price. Analyst inference
Evidence
- Original source link unavailable